Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Supporting quality of life
The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
Latest news
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
Journal ArticleOncologist, 27 (10), 2022.
Abstract | Links: 
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Journal ArticleBreast Cancer Res Treat, 193 (3), 2022.
| Links:
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Journal ArticleBreast Cancer Res Treat, 193 (3), 2022.
Abstract | Links:
Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study
Journal ArticleSupport Care Cancer, 30 (6), 2022.
Abstract | Links:
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
Journal ArticleBreast Cancer Res Treat, 192 (1), 2022.
Abstract | Links:
Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial
Journal ArticleAnn Surg Oncol, 29 (4), 2022.
Abstract | Links:
Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada
Journal ArticleJ Pers Med, 11 (9), 2021.
Abstract | Links:
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Journal ArticleBreast Cancer Res Treat, 187 (1), 2021.
Abstract | Links:
DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood
Journal ArticleCancers (Basel), 12 (11), 2020.
Abstract | Links:
Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach
Journal ArticleRes Social Adm Pharm, 16 (12), 2020.
Abstract | Links:
Active projects
- A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in women with estrogen receptor-positive primary breast cancer, from 2016-03-30 to 2025-12-25
- Breast adipocyte hypertrophy: a novel biomarker to predict breast cancer survival, from 2022-01-01 to 2023-12-31
- Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2024-09-30
- Excellence in advanced cancer clinical trials initiative (the ExACCT Initiavive) , from 2017-01-18 to 2025-03-31
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
- Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, from 2018-10-01 to 2026-09-30
- Towards better outcomes for young women with breast cancer : A pan-canadian collaborative - Reducing the bUrden of Breast cancer in Young women (RUBY), from 2016-03-10 to 2025-12-25
Recently finished projects
- Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2023-03-01
- Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08
- Utilisation de l'intelligence artificielle afin de maintenir automatiquement le registre national de suivi en cancer du sein et du projet de recherche en cancer du sein associé, from 2019-01-01 to 2021-12-31